Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1981 Jul;44(1):117–123. doi: 10.1038/bjc.1981.156

Combination therapy of a mouse sarcoma using razoxane and electron irradiation.

M B Grimshaw, R W Davies, W S Hall
PMCID: PMC2010644  PMID: 7259958

Abstract

The combination of a single dose of razoxane (ICRF 159) with a single dose of electron radiation has been studied with the murine sarcoma S180. A drug dose of 30 mg/kg combined with radiation produced a greater tumour response than either agent alone, but it was not possible to establish whether the effect was more than additive. Direct measurements of tumour and s.c. oxygen concentrations and studies of tumour-cell respiration were carried out after various razoxane treatments in an attempt to elucidate mechanisms of action. There were no indications at the drug dose levels used in the radiation studies of any significant changes in tissue oxygenation or cellular respiration.

Full text

PDF
117

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakowski M. T., Macdonald E., Mould R. F., Cawte P., Sloggem J., Barrett A., Dalley V., Newton K. A., Westbury G., James S. E. Double blind controlled clinical trial of radiation plus razoxane (ICRF 159) versus radiation plus placebo in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys. 1978 Jan-Feb;4(1-2):115–119. doi: 10.1016/0360-3016(78)90125-6. [DOI] [PubMed] [Google Scholar]
  2. Bates T. A clinical evaluation of ICRF 159 as a radiosensitising agent. Int J Radiat Oncol Biol Phys. 1978 Jan-Feb;4(1-2):127–131. doi: 10.1016/0360-3016(78)90127-x. [DOI] [PubMed] [Google Scholar]
  3. CHANCE B., HESS B. Metabolic control mechanisms. I. Electron transfer in the mammalian cell. J Biol Chem. 1959 Sep;234:2404–2412. [PubMed] [Google Scholar]
  4. Creaven P. J., Cohen M. H., Hansen H. H., Selawry O. S., Taylor S. G., 3rd Phase I clinical trial of a single-dose and two weekly schedules of ICRF-159 (NSC-129943). Cancer Chemother Rep. 1974 May-Jun;58(3):393–400. [PubMed] [Google Scholar]
  5. Davies R. W., Hall W. Oxygen cathodes for clinical measurements. Phys Med Biol. 1973 Mar;18(2):279–281. doi: 10.1088/0031-9155/18/2/313. [DOI] [PubMed] [Google Scholar]
  6. Denekamp J., Harris S. R. Tests of two electron-affinic radiosensitizers in vivo using regrowth of an experimental carcinoma. Radiat Res. 1975 Feb;61(2):191–203. [PubMed] [Google Scholar]
  7. Hellmann K., Murkin G. E. Synergism of ICRF 159 and radiotherapy in treatment of experimental tumors. Cancer. 1974 Oct;34(4):1033–1039. doi: 10.1002/1097-0142(197410)34:4<1033::aid-cncr2820340412>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  8. Hellmann K., Ryall R. D., Macdonald E., Newton K. A., James S. E., Jones S. Comparison of radiotherapy with and without razoxane (ICRF 159) in the treatment of soft tissue sarcomas. Cancer. 1978 Jan;41(1):100–107. doi: 10.1002/1097-0142(197801)41:1<100::aid-cncr2820410115>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  9. Norpoth K., Schaphaus A., Ziegler H., Witting U. Combined treatment of the Walker tumour with radiotherapy and ICRF 159. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1974;82(4):329–334. doi: 10.1007/BF00285567. [DOI] [PubMed] [Google Scholar]
  10. Peters L. J. Modification of the radiocurability of a syngeneic murine squamous carcinoma by its site of growth, by electron-affinic drugs, and by ICRF 159. Br J Radiol. 1976 Aug;49(584):708–715. doi: 10.1259/0007-1285-49-584-708. [DOI] [PubMed] [Google Scholar]
  11. Roberts J. R., Riddle H. C., Davies R. W. An improved apparatus for the measurement of oxygen concentration. Phys Med Biol. 1975 Jul;20(4):637–644. doi: 10.1088/0031-9155/20/4/012. [DOI] [PubMed] [Google Scholar]
  12. Ryall R. D., Bates T., Newton K. A., Hellmann K. Combination of radiotherapy and razoxane (ICRF 159) for chondrosarcoma. Cancer. 1979 Sep;44(3):891–895. doi: 10.1002/1097-0142(197909)44:3<891::aid-cncr2820440315>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  13. Salsbury A. J., Burrage K., Hellmann K. Histological analysis of the antimetastatic effect of (plus or minus)-1,2-bis(3,5-dioxopiperazin-1-yl)propane. Cancer Res. 1974 Apr;34(4):843–849. [PubMed] [Google Scholar]
  14. Sheldon P. W., Hill S. A. Hypoxic cell radiosensitizers and local control by X-ray of a transplanted tumour in mice. Br J Cancer. 1977 Jun;35(6):795–808. doi: 10.1038/bjc.1977.121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Shewell J., Davies R. W. Combined therapy of the spontaneous mouse mammary tumour: methotrexate and hyperbaric oxygen irradiation. Eur J Cancer. 1977 Sep;13(9):977–984. doi: 10.1016/0014-2964(77)90176-1. [DOI] [PubMed] [Google Scholar]
  16. Spittle M. F., Bush H., James S. E., Hellmann K. Clinical trial of razoxane and radiotherapy for inoperable carcinoma of the bronchus. Int J Radiat Oncol Biol Phys. 1979 Sep;5(9):1649–1651. doi: 10.1016/0360-3016(79)90790-9. [DOI] [PubMed] [Google Scholar]
  17. Taylor I. W., Bleehen N. M. Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line. Br J Cancer. 1977 May;35(5):587–594. doi: 10.1038/bjc.1977.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Thomlinson R. H., Craddock E. A. The gross response of an experimental tumour to single doses of x-rays. Br J Cancer. 1967 Mar;21(1):108–123. doi: 10.1038/bjc.1967.10. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES